A French trial from 2020 investigated the efficacy and safety of a different EGFR mAb, necitumumab, in combination with pembrolizumab for stage IV NSCLC in the second-line setting after progression on platinum-based chemotherapy or targeted therapy [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.